# Targeting epigenetic regulators to boost T cell immunotherapy against cancer

## TL;DR

This paper reviews how epigenetic changes affect T-cell immunotherapy and how targeting these changes could improve cancer treatments.

## Contribution

The paper provides a comprehensive review of epigenetic regulators and their impact on T-cell immunotherapy outcomes.

## Key findings

- Epigenetic regulators influence T-cell differentiation and function.
- Targeting epigenetic pathways can enhance CAR-T and TCR-based therapies.
- Epigenetic changes contribute to T-cell exhaustion and lineage commitment.

## Abstract

Epigenetic regulation is crucial in directing T-cell differentiation, function, and fate, thereby influencing the success of T-cell-based immunotherapies. This review begins with an overview of the evolution of T-cell immunotherapies in cancer treatment. We then examine key epigenetic regulators—such as DNA methylation, mRNA methylation, and histone methylation—and their roles in shaping T-cell states during infection and tumorigenesis. The contributions of these regulators to T-cell exhaustion and lineage commitment are discussed in the context of immunotherapy efficacy. We highlight recent advances in targeting epigenetic pathways to enhance CAR-T and TCR-based therapies and conclude with current challenges and emerging strategies to improve the durability and effectiveness of adoptive T-cell therapies.